MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, warrants...
$23,216K
Proceeds from the
exercise of warrants
$15,298K
Net cash provided by
financing activities
$38,514K
Net change in cash
and cash...
$2,714K
Canceled cashflow
$35,800K
Stock-based compensation
$19,163K
Accounts payable
$2,884K
Net cash used in
operating activities
-$35,800K
Canceled cashflow
$22,047K
Net loss
-$52,599K
Prepaid expenses and
other current assets
$4,827K
Accrued liabilities
-$421K
Back
Back
Cash Flow
source: myfinsight.com
TENAX THERAPEUTICS, INC. (TENX)
TENAX THERAPEUTICS, INC. (TENX)